Rezolute Added to Russell Microcap Index

Rezolute Added to Russell Microcap

CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company

developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Russell

Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens

Membership in the Russell Microcap Index, which remains

in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership

for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

"We're thrilled to be added to the Russell Microcap

Index," said Nevan Elam, Chief Executive Officer and Founder of Rezolute. "This inclusion serves as an exciting opportunity

to introduce a wider investor audience to Rezolute's therapeutic candidates to treat metabolic

diseases related to chronic glucose imbalance."

Russell indexes are widely used by investment managers and institutional

investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against

Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap Index

and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About Rezolute, Inc.

Rezolute is developing transformative therapies for metabolic diseases related to chronic glucose

imbalance. The Company's lead clinical asset, RZ358, is in Phase 2b development for treatment of congenital hyperinsulinism

(CHI), a rare pediatric endocrine disorder. The Company is also developing RZ402, an orally available plasma kallikrein inhibitor, for

FTSE Russell is a global index leader that provides innovative benchmarking,

analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets

and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional

and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading

asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance

and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design

and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell

is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is

also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

Forward-Looking Statements

release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain forward-looking

statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E

of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions

for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for

purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans,

strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe,"

"estimate," "expect," "intend," "plan," "project," "seek," "strive,"

"try," or future or conditional verbs such as "could," "may," "should," "will," "would,"

or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly,

actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking

statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no

obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements

Media and Investor Contact